Indivior
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Indivior sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Indivior: 37 sponsored US clinical trials, none currently recruiting.
Indivior sponsors 37 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 36 completed. 12 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid-Related Disorders, with 4 trials.
Top-decile sponsor footprint
Indivior ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
36 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
37 total, page 1 of 1
INDV-6001 Multiple-Dose Pharmacokinetic Study
NCT06576843
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
NCT06384157
Evaluating the SUBLOCADE Treatment Exit Strategy
NCT05878210
SUBLOCADE Long-term Outcomes
NCT05860959
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
NCT05974046
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
NCT05694533
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
NCT05704543
Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder
NCT04976855
Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
NCT04995029
An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term
NCT04577144
INDV-2000 First in Human
NCT04413552
SUBLOCADE Rapid Initiation Extension Study
NCT04060654
SUBLOCADE Rapid Initiation Study
NCT03993392
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
NCT03978832
Evaluation of Long-term Buprenorphine Plasma Exposure
NCT03752528
Open-Label Treatment Extension Study
NCT02896296
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
NCT02687984
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
NCT02511886
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
NCT02559973
An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery
NCT03604861
Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder
NCT02510014
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
NCT02357901
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
NCT02203838
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
NCT02109562
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
NCT02038790
Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
NCT02044094
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
NCT01846481
Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects
NCT01738503
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
NCT01846455
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
NCT01677377
Single Ascending Dose Study of RBP-6000
NCT03002961
Single Ascending Dose Study of RBP-7000
NCT02768649
Single-dose, Study of RBP-6000 in Opioid Dependent Individuals
NCT02765867
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
NCT02765555
Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
NCT00637000
Safety and Tolerability of Buprenorphine/Naloxone Film Strips
NCT00640835
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
NCT00838396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 10 |
| Phase 3 | 5 |
| Phase 4 | 7 |
Therapeutic Areas
How the Indivior early-phase archive is shaped
37 indexed studies, none listed as recruiting (0% open); 36 completed (97%).
Phase mix: 12 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Opioid-Related Disorders (4 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Indivior: archived-pipeline peers nationwide
Peers matched on 37 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Indivior sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 archived trials
- Appalachian State University · 37 trials · 3% recruiting
- Bracco Diagnostics · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Indivior page
37 registered trials is a research-attention snapshot, not an endorsement of Indivior or any single study.
- None of Indivior's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Opioid-Related Disorders is the condition Indivior studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Indivior pipeline card: 37 registered trials from official public datasets.Report a data error.